Genmab ponders next steps after preliminary cancer candidate results

Genmab and partner Abbvie are ready to confer with global health authorities about planning the next steps for their cancer drug.

Photo: Joost Melis / Genmab / PR

Biotech firm Genmab and partner Abbvie have reported topline results from a phase I/II study of candidate epcoritamab, a subcutaneous drug against large B-cell lymphoma (LBCL), the companies have announced in a joint press release.

Based on the preliminary results, the two firms will now ”engage global health authorities to determine next steps,” the statement reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs